NEW YORK (GenomeWeb) – Interpace Diagnostics announced after the close of the market on Tuesday that its third quarter revenues grew 38 percent year over year, surpassing the consensus Wall Street estimate.

For the three months ended Sept. 30, the Parsippany, New Jersey-based firm posted $5.8 million in revenues compared to $4.2 million in the year-ago period. It beat the analysts' average estimate of $5.6 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.